EVIDENCIAS CIENTÍFICAS CBD

ShanaCBD®️ es amante de toda investigación y evidencias científicas en el ámbito internacional. Es por ello, que le adjuntamos numerosos estudios de reconocido prestigio que justifican los Beneficios asociados al CBD.

Aumento de la concentración & CBD:

• • Cannabinoids in attention-deficit/hyperactivity disorder: A randomised-controlled trial; European Neuropsychopharmacolology; May 30, 2017; Cooper RE, Williams E, Seegobin S, Tye C, Kuntsi J, Asherson P; https://www.ncbi.nlm.nih.gov/pubmed/28576350
  • Modulation of cognitive and emotional processing by cannabidiol: the role of the anterior cingulate cortex; Frontiers in Human Neurosciences; Apr 18, 2013; Mikael A. Kowal, Arno Hazekamp, Lorenza S Colzato, Henk van Steenbergen, and Bernhard Hommel; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3629308/
  • Therapeutic Effects of Prolonged Cannabidiol Treatment on Psychological Symptoms and Cognitive Function in Regular Cannabis Users: A Pragmatic Open-Label Clinical Trial; Cannabis and Cannabinoid Research; March 1, 2018; Nadia Solowij, Samantha J. Broyd, Camilla Beale, Julie-Anne Prick, Lisa-marie Greenwood, Hendrika van Hell, Chao Suo, Peter Galettis, Nagesh Pai, Shanlin Fu, Rodney J. Croft, Jennifer H. Martin, and Murat Yücel; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5870061/

Ansiedad, estrés & CBD

• • Cannabidiol as a Therapeutic Alternative for Post-traumatic Stress Disorder: From Bench Research to Confirmation in Human Trials; Frontiers in Neuroscience; July 24, 2018; Rafael M. Bitencourt and Reinaldo N Takahashi; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6066583/
  • Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders; Philosophical Transactions of The Royal Society B Biological Sciences; Dec 5, 2012; Campos AC, Moreira FA, Gomes FV, Del Bel EA, Guimarães FS; https://www.ncbi.nlm.nih.gov/pubmed/23108553/

Ansiedad, depresión & CBD

• • Cannabidiol as a Potential Treatment for Anxiety Disorders; Neurotherapeutics; September 4, 2015; Esther M Blessing, Maria M. Steenkamp, Jorge Manzanares, and Charles R Marmar; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4604171/
  • Evidences for the Anti-panic Actions of Cannabidiol; Current Neuropharmacology; February 2017; Vanessa P Soares and Alline C Campos; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412699/

Mejora del humor & CBD

• • Cannabidiol induces rapid-acting antidepressant-like effects and enhances cortical 5-HT/glutamate neurotransmission: role of 5-HT1A receptors; Neuropharmacology; December 19, 2015; Linge R, Jiménez-Sánchez L, Campa L, Pilar-Cuéllar F, Vidal R, Pazos A, Adell A, Díaz Á; https://www.ncbi.nlm.nih.gov/pubmed/26711860

Dolores e inflamación & CBD

• • Cannabinoids in the management of difficult to treat pain; Therapeutics and Clinical Risk Management; February 4, 2008; Ethan B Russo; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2503660/
  • Cannabinoid Delivery Systems for Pain and Inflammation Treatment; Molecules; September 27, 2018; Natascia Bruni, Carlo Della Pepa, Simonetta Oliaro-Bosso, Enrica Pessione, Daniela Gastaldi, and Franco Dosio; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6222489/

Dolores menstruales & CBD

• • The Clinical Significance of Endocannabinoids in Endometriosis Pain Management; Cannabis and Cannabinoid Research; April 1, 2017; Jerome Bouaziz, Alexandra Bar On, Daniel S. Seidman, and David Soriano; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5436335/

Sueño & CBD

• • No Acute Effects of Cannabidiol on the Sleep-Wake Cycle of Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study; Frontiers in Pharmacology; April 5, 2018; Ila M P Linares, Francisco S Guimaraes, Alan Eckeli, Ana C S Crippa,Antonio W Zuardi, Jose D S Souza, Jaime E Hallak, and José AS Crippa; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5895650/
  • Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson’s disease patients: a case series; Journal of Clinical Pharmacy and Therapeutics, May 21, 2014; Chagas MH1, Eckeli AL, Zuardi AW, Pena-Pereira MA, Sobreira-Neto MA, Sobreira ET, Camilo MR, Bergamaschi MM, Schenck CH, Hallak JE, Tumas V, Crippa JA; https://www.ncbi.nlm.nih.gov/pubmed/24845114

Los comercializamos con la certificación de análisis de laboratorio (THC <0.2%) acorde a los requisitos de la legislación europea y de conformidad al Reglamento (UE) No 639/2014 de la Comisión de 11 de marzo de 2014; y el Reglamento europeo n. 1307/2013 del Parlamento Europeo y del Consejo.